Back to Screener

Telix Pharmaceuticals Limited American Depositary Shares (TLX)

Price$10.73

Favorite Metrics

Price vs S&P 500 (26W)3.48%
Price vs S&P 500 (4W)13.25%

All Metrics

Price vs S&P 500 (YTD)39.25%
10-Day Avg Trading Volume0.28M
3-Month Avg Trading Volume0.24M
52-Week Price Return-35.07%
52-Week High$20.00
26-Week Price Return12.23%
13-Week Price Return40.94%
3-Month Return Std Dev69.47%
Price vs S&P 500 (52W)-70.16%
Year-to-Date Return43.39%
5-Day Price Return-4.45%
Month-to-Date Return12.23%
Price vs S&P 500 (13W)38.08%
52-Week Low$6.28

Industry Peers — Pharmaceuticals(309)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
TLXTelix Pharmaceuticals Limited American Depositary Shares
$10.73
LLYEli Lilly & Co.
13.45x44.70%83.04%27.59%$919.90
JNJJohnson & Johnson
5.82x7.87%67.95%14.90%$230.69
ABBVABBVIE INC.
5.97x8.57%71.62%-2.88%$203.71
MRKMerck & Co., Inc.
4.51x1.31%78.55%21.23%$117.10
AZNAstraZeneca PLC
5.39x8.63%81.31%21.88%$200.69
NVSNovartis AG
4.87x8.91%75.82%15.26%$150.99
NVONovo-Nordisk A/S
3.74x6.43%80.98%20.66%$40.46
ABTAbbott Laboratories
3.71x6.59%56.50%8.20%$96.00
PFEPfizer Inc.
2.50x-1.64%75.81%-3.51%$27.52
BMYBristol-Myers Squibb Co.
2.52x-0.22%72.63%$59.13

About

Telix develops radiopharmaceuticals, which combine radioisotopes with targeted molecules to diagnose and treat cancers. The company generates revenue from U.S. sales of Illuccix, a prostate cancer imaging agent, while advancing additional radiopharmaceutical candidates through its pipeline.